BlueCrest Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

BlueCrest Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-282,795	Closed	-$1.46M	–	1932
2018 Q1	$1.46M	Buy	+282,795	New	+$2.01M	0.05%	381
2015 Q2	–	Sell	-38,166	Closed	-$441K	–	958
2015 Q1	$441K	Buy	+38,166	New	+$442K	0.02%	476

Other funds holding SRNE

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlueCrest Capital Management's SRNE Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2018, closing a stake of 282,795 shares — an estimated $1.46M sold.

BlueCrest Capital Management first reported a position in SRNE in Q1 2015 and held it in 2 quarters. The position peaked at $1.46M in Q1 2018. 94 funds tracked by Wall St. Rank hold SRNE as of Q2 2018.

BlueCrest Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 282,795 Sorrento Therapeutics, Inc. shares in Q2 2018, an estimated $1.46M.
BlueCrest Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
BlueCrest Capital Management's Sorrento Therapeutics, Inc. position peaked at $1.46M in Q1 2018.
94 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.